New search Hide text from Guidelines
A ALIMENTARY TRACT AND METABOLISMA10 DRUGS USED IN DIABETES
A10B BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Fixed combinations of blood glucose lowering drugs and lipid modifying agentes are classified here.
A10BA Biguanides
A10BB Sulfonylureas
| The DDD for micronized glibenclamide is lower compared to non-micronized formulations, due to higher bioavailability. The DDD for gliclazide is based on the modified release formulation. |
A10BC Sulfonamides (heterocyclic)
A10BD Combinations of oral blood glucose lowering drugs
Combinations with thioctic acid are allowed in A10BD05.
| It has been considered most appropriate to assign fixed DDDs based on the average use of the different combinations without considering and comparing the strengths of the various components. One UD is the fixed DDD for products dosed as 1 tablet daily whereas two UD is the fixed DDD for products dosed as 2 tablets daily. The assigned DDDs cannot always be compared with the DDDs assigned for plain preparations. See list of DDDs for combined products, www.whocc.no. |
A10BF Alpha glucosidase inhibitors
A10BG Thiazolidinediones
| The DDD for troglitazone is based on combination therapy. The DDDs for rosiglitazone and pioglitazone are based on monotherapy. |
A10BH Dipeptidyl peptidase 4 (DPP-4) inhibitors
A10BJ Glucagon-like peptide-1 (GLP-1) analogues
A10BK Sodium-glucose co-transporter 2 (SGLT2) inhibitors
Inhibitors of SGLT1 and SGLT2, e.g. sotagliflozin, are also classified here.
A10BX Other blood glucose lowering drugs, excl. insulins
Low strength tablets (e.g. 0.8 mg) of bromocriptine are classified in G02CB01.
Nateglinide in combination with thioctic acid is classified in A10BX03.
Last updated: 2024-01-26